Induced pluripotent stem cell (iPSC) technology, based on autologous cells’ reprogramming to the embryonic state, is a new approach in regenerative medicine. Current advances in iPSC technology hav...
In the last 2 decades, a wide variety of studies have been conducted on epigenetics and its role in various cancers. A major mechanism of epigenetic regulation is DNA methylation, including aberran...
Pancreatic cancer is marked by a poor prognosis and an exceptionally high mortality rate, with its aggressive nature contributing to its classification as a highly malignant disease. For effective therapeutic strategies, the development of sophisticated and regulated DNA manipulation methods is essential. Originally part of the prokaryotic immune system, CRISPR/Cas has emerged as a pivotal genome-editing tool with promising applications in pancreatic cancer research and therapy. This gene editing method is known for simplicity, rapid advancement, and superior precision compared to earlier techniques. Its adaptability allows precise gene editing for therapeutic purposes, including oncogene silencing and correction of pathogenic mutations. Additionally, CRISPR-driven gene editing has facilitated the development of pancreatic cancer models, which serve as valuable platforms for drug discovery and personalized treatment strategies, offering deeper insights into the genetic landscape of pancreatic tumors. This article provides an overview of the current applications of CRISPR technology in gene therapy and cancer research, particularly in the context of pancreatic cancer, and lays the foundation for future studies.
Epigenetics has an important role in gene regulation and other cellular processes. DNA methylation, as one of the main mechanisms of epigenetics, is a type of post-replication modifications. Aberrant DNA methylation can alter gene expression patterns; so, plays a considerable role in the pathogenesis of many diseases. DNA methylation alterations in promoter of specific genes can be used for diagnosis and proprietary targets for treatment that known as “biomarker”. Early diagnosis and prevention may be possible by these biomarkers. According to the recent studies, DNA methylation abnormalities have an important role in retinogenesis and pathogenesis of retinal diseases. Retinal diseases are the main cause of blindness and severe visual loss in the world and will continue to increase. Also, they inflict enormous burden on society and health care systems. Therefore, it is important to focus on the better recognition and prevention of retinal diseases, and fining new targets for treatment. DNA methylation lionized as attractive therapeutic targets due to its reversibility. Epigenetic therapy has a high potency in treatment of retinal diseases. Here, we reviewed the DNA and histone methylation alterations in common retinal diseases, focusing on age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment (RD), retinitis pigmentosa, retinal aging and retinoblastoma, and then we surveyed some new approaches of epigenetic therapy in retinal disorders.